BACKGROUND: Despite more aggressive screening across all demographics and gradual declines in mortality related to prostate cancer (PCa) in the United States, disparities among populations persist. A substantial proportion of African American men (AAM) have a higher overall incidence, earlier age of onset, increased proportion of clinically advanced disease, and increased bone metastases and mortality from PCa compared to European American men (EAM). Limited early evidence indicates that underlying causes for disparities may be observed in tumor-specific gene expression programs. METHODS: This study used microarray-based methods to measure expression levels for 517 genes that were previously associated with PCa in archived formalin-fixed paraffin embedded (FFPE) specimens; testing the hypothesis that gene expression features of functional consequence to cancer distinguish PCa from AAM and EAM. A t test was conducted comparing AAM to EAM expression levels for each probe on the array. RESULTS: Analysis of 639 tumor samples (270 AAM, 369 EAM) showed that 95 genes were overexpressed specifically in PCa from AAM relative to EAM and 132 were overexpressed in PCa from EAM relative to AAM. Furthermore, systems-level analyses highlight the relevant signaling pathways and functions associated with the EAM- or AAM-specific overexpressed gene sets, for example, inflammation and lipid metabolism. CONCLUSIONS: Results here bring further understanding to the potential for molecular differences for PCa in AAM versus EAM. IMPACT: The results support the notion that therapeutic benefits will be realized when targeted treatments are designed to acknowledge and address a greater spectrum of PCa subtypes and molecular distinctions.
BACKGROUND: Despite more aggressive screening across all demographics and gradual declines in mortality related to prostate cancer (PCa) in the United States, disparities among populations persist. A substantial proportion of African American men (AAM) have a higher overall incidence, earlier age of onset, increased proportion of clinically advanced disease, and increased bone metastases and mortality from PCa compared to European American men (EAM). Limited early evidence indicates that underlying causes for disparities may be observed in tumor-specific gene expression programs. METHODS: This study used microarray-based methods to measure expression levels for 517 genes that were previously associated with PCa in archived formalin-fixed paraffin embedded (FFPE) specimens; testing the hypothesis that gene expression features of functional consequence to cancer distinguish PCa from AAM and EAM. A t test was conducted comparing AAM to EAM expression levels for each probe on the array. RESULTS: Analysis of 639 tumor samples (270 AAM, 369 EAM) showed that 95 genes were overexpressed specifically in PCa from AAM relative to EAM and 132 were overexpressed in PCa from EAM relative to AAM. Furthermore, systems-level analyses highlight the relevant signaling pathways and functions associated with the EAM- or AAM-specific overexpressed gene sets, for example, inflammation and lipid metabolism. CONCLUSIONS: Results here bring further understanding to the potential for molecular differences for PCa in AAM versus EAM. IMPACT: The results support the notion that therapeutic benefits will be realized when targeted treatments are designed to acknowledge and address a greater spectrum of PCa subtypes and molecular distinctions.
Authors: N Gokce; M Holbrook; S J Duffy; S Demissie; L A Cupples; E Biegelsen; J F Keaney; J Loscalzo; J A Vita Journal: Hypertension Date: 2001-12-01 Impact factor: 10.190
Authors: Paul L Nguyen; Jing Ma; Jorge E Chavarro; Matthew L Freedman; Rosina Lis; Giuseppe Fedele; Christopher Fiore; Weiliang Qiu; Michelangelo Fiorentino; Stephen Finn; Kathryn L Penney; Anna Eisenstein; Fredrick R Schumacher; Lorelei A Mucci; Meir J Stampfer; Edward Giovannucci; Massimo Loda Journal: J Clin Oncol Date: 2010-08-02 Impact factor: 44.544
Authors: Christopher L Amling; Robert H Riffenburgh; Leon Sun; Judd W Moul; Raymond S Lance; Leo Kusuda; Wade J Sexton; Douglas W Soderdahl; Timothy F Donahue; John P Foley; Andrew K Chung; David G McLeod Journal: J Clin Oncol Date: 2003-12-22 Impact factor: 44.544
Authors: Philip Rosen; David Pfister; Denise Young; Gyorgy Petrovics; Yongmei Chen; Jennifer Cullen; Diana Böhm; Sven Perner; Albert Dobi; David G McLeod; Isabell A Sesterhenn; Shiv Srivastava Journal: Urology Date: 2012-08-28 Impact factor: 2.649
Authors: Jennifer M Post; Jennifer L Beebe-Dimmer; Hal Morgenstern; Christine Neslund-Dudas; Cathryn H Bock; Nora Nock; Andrew Rundle; Michelle Jankowski; Benjamin A Rybicki Journal: Prostate Cancer Date: 2011-09-25
Authors: Anna Dubrovska; Jimmy Elliott; Richard J Salamone; Gennady D Telegeev; Alexander E Stakhovsky; Ihor B Schepotin; Feng Yan; Yan Wang; Laure C Bouchez; Sumith A Kularatne; James Watson; Christopher Trussell; Venkateshwar A Reddy; Charles Y Cho; Peter G Schultz Journal: PLoS One Date: 2012-02-16 Impact factor: 3.240
Authors: Rahul Kumar; Tariq A Bhat; Elise M Walsh; Ajay K Chaudhary; Jordan O'Malley; Johng S Rhim; Jianmin Wang; Carl D Morrison; Kristopher Attwood; Wiam Bshara; James L Mohler; Neelu Yadav; Dhyan Chandra Journal: Cancer Res Date: 2019-02-14 Impact factor: 12.701
Authors: Scott P Kelly; Philip S Rosenberg; William F Anderson; Gabriella Andreotti; Naji Younes; Sean D Cleary; Michael B Cook Journal: Eur Urol Date: 2016-07-27 Impact factor: 20.096
Authors: Adriana C Vidal; Lauren E Howard; Amanda De Hoedt; Christopher J Kane; Martha K Terris; William J Aronson; Matthew R Cooperberg; Christopher L Amling; Stanislav Lechpammer; Scott C Flanders; Stephen J Freedland Journal: Cancer Date: 2018-11-14 Impact factor: 6.860
Authors: Isaac J Powell; Fawn D Vigneau; Cathryn H Bock; Julie Ruterbusch; Lance K Heilbrun Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-05-06 Impact factor: 4.254